Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.

Peng W, Zhang X, Mohamed N, Inghirami G, Takeshita K, Pecora A, Nardone LL, Pincus SE, Casey LS, Spitalny GL.

Cancer Immunol Immunother. 2005 Dec;54(12):1172-9. Epub 2005 Apr 22.

PMID:
15846490
2.

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.

Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP.

Blood. 2003 Feb 1;101(3):1071-9. Epub 2002 Sep 5.

3.

Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.

Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A.

Ann N Y Acad Sci. 2009 Sep;1173:865-73. doi: 10.1111/j.1749-6632.2009.04803.x. Erratum in: Ann N Y Acad Sci. 2010 Aug;1204:198. Eliezer, Rachmilewitz [corrected to Rachmilewitz, Eliezer A]; Ami, Schattner [corrected to Schattner, Ami].

PMID:
19758239
4.

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.

Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB.

Clin Cancer Res. 2008 Jul 15;14(14):4650-7. doi: 10.1158/1078-0432.CCR-07-4405.

5.

Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Cvetković RS, Perry CM.

BioDrugs. 2006;20(4):253-7. Review.

PMID:
16831024
7.

The therapeutic use of rituximab in non-Hodgkin's lymphoma.

Marcus R, Hagenbeek A.

Eur J Haematol Suppl. 2007 Jan;(67):5-14. Review.

PMID:
17206982
8.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Cvetković RS, Perry CM.

Drugs. 2006;66(6):791-820. Review.

PMID:
16706552
10.

Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer.

Beum PV, Lindorfer MA, Hall BE, George TC, Frost K, Morrissey PJ, Taylor RP.

J Immunol Methods. 2006 Dec 20;317(1-2):90-9. Epub 2006 Oct 10.

PMID:
17067631
12.
13.

Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.

Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, Golay J.

J Immunol. 2013 Jan 1;190(1):231-9. doi: 10.4049/jimmunol.1202645. Epub 2012 Dec 5.

14.

Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.

Guo B, Ma ZW, Li H, Xu GL, Zheng P, Zhu B, Wu YZ, Zou Q.

Clin Immunol. 2008 Aug;128(2):155-63. doi: 10.1016/j.clim.2008.03.507. Epub 2008 May 23.

PMID:
18502181
16.

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.

Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M.

Am J Hematol. 2009 Sep;84(9):553-9. doi: 10.1002/ajh.21468.

17.

Mechanism of action of rituximab.

Cerny T, Borisch B, Introna M, Johnson P, Rose AL.

Anticancer Drugs. 2002 Nov;13 Suppl 2:S3-10. Review.

PMID:
12710585
18.

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP.

J Immunol. 2009 Jul 1;183(1):749-58. doi: 10.4049/jimmunol.0900632. Epub 2009 Jun 17.

19.

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J, Introna M.

Br J Haematol. 2001 Sep;114(4):800-9.

PMID:
11564066
20.

rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.

Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X.

Clin Cancer Res. 2011 Nov 1;17(21):6702-11. doi: 10.1158/1078-0432.CCR-11-0647. Epub 2011 Sep 14.

Items per page

Supplemental Content

Write to the Help Desk